# Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis

> **NCT01638520** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 32 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Pascolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01638520
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2017-02
- **Final completion:** 2017-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01638520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01638520, "Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01638520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*